Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cortex (Cor) [formerly CORX] -- Ignore unavailable to you. Want to Upgrade?

To: RBlatch who wrote (794)	4/6/1999 5:29:00 PM
From: James M. Bash	Read Replies (1) \| Respond to of 1255

From the press release: Additionally, Dr. Simmon reported, "Preliminary results from our clinical trial in patients with schizophrenia suggest that Ampakines may substantially improve both memory and cognition. This trial also provided the first evidence that Ampakines might be useful in treating ADD." Additional results from this trial will be presented on April 18, 1999, by Donald Goff, M.D. at the International Society for Schizophrenia Research in Santa Fe, New Mexico. Dr. Goff is Medical Director, Freedom Trail Clinic, Erich Lindemann Mental Health Center, Harvard Medical School in Boston, MA. Published studies demonstrate that Ampakines can cause a statistically significant increase in the memory of elderly animals and humans. In addition to the trial in patients with schizophrenia, Cortex's AMPA modulating compound CX516 is currently in a Phase I/IIa trial in patients with Alzheimer's disease at the National Institutes of Health in Bethesda, MD.